FTC's Generic Market Analysis Forcing Divestures Even In Diverse Categories
This article was originally published in The Pink Sheet Daily
Executive Summary
Hikma must divest rights to three drugs under Roxane Labs deal as Federal Trade Commission aims to preserve as many as five competitors in some markets.